Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. - Wikidata - wikimedia - TriplyDB

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

http://www.wikidata.org/entity/Q36510153

about

EMT-Inducing Molecular Factors in Gynecological Cancers Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions.Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Promising novel therapies for the treatment of endometrial cancer ErbB/EGF signaling and EMT in mammary development and breast cancer.A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.Targeting Notch signaling pathway to overcome drug resistance for cancer therapy Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer A comparison of epithelial-to-mesenchymal transition and re-epithelialization Cancer stem cells and chemoresistance: The smartest survives the raid The tumor microenvironment is a dominant force in multidrug resistance.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition Current treatment strategies for endometrial cancer.Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.Unresolved issues in the management of endometrial cancer.Emerging therapeutic targets in endometrial cancer.Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?Medical therapy of endometrial cancer: current status and promising novel treatments.The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis.Anthracycline-based chemotherapy in metastatic endometrial carcinoma: an update.Emerging drugs for endometrial cancer.Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.EGFR and HER2 inhibition in pancreatic cancer.Targeted endometrial cancer therapy as a future prospect.Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression.Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

P2860

Q26781912-00FC9301-BDB9-4FF9-B235-A5DC8B874A96 Q28066130-42B648FC-AC38-450D-B805-1A20058E351A Q28074769-95FC1DBB-F5B1-4801-98C2-F62D73661895 Q30988276-770F9FA9-35BA-4C1F-9D52-5904FFBD7544 Q33709820-8D0BAAA2-40AC-41F5-A7ED-96E93EB29EC5 Q33750719-FBD83A4F-05BD-438C-87E5-AAE2EF0517AC Q33920661-1705F662-7A13-4056-B81D-5B7D42B46190 Q33927493-6032A9F2-D9EC-4CA2-813C-044F5BB81D7A Q34062367-75AEF8A6-F105-4456-85F4-EF43168B9258 Q34205088-A509E33C-7167-441D-93B4-882EE4B5254A Q34208986-5EBD2B8F-F6A3-434B-921A-A1F2DC255227 Q34636527-E9C1EA49-BC21-433F-8894-462D577CFEE7 Q35235832-AEC5A063-1946-47F2-94EA-541B71675F1D Q35287729-BFEF988C-6FAE-44EF-922D-BC551CFABC21 Q35870242-F022223F-350A-46F7-893C-6FA0605EDD18 Q36456386-2091F3FC-87DA-4212-83BA-95D4A8A960F9 Q36678367-E558403E-8EDA-46A6-B909-7263ECE83027 Q36730432-E66FD0BD-22F7-4955-8DAD-BD8FC44A02D2 Q36856829-7EEB9D1C-7C44-42C0-B571-829D242B12BA Q36967905-DF5BE711-D188-475D-82BE-708A891A5A3F Q37080967-DAE79ED6-0142-4A09-A5EC-B01D224CD084 Q37169972-19CF48A4-92FB-4D3F-92E3-7F4433219F09 Q37202781-8C3A9B63-3951-40A7-A6BD-456D3C101E54 Q37657171-7E436323-27C8-42BA-AE22-1A739604C6DA Q37671783-FA283FF1-908C-4B85-91EF-C89E55EB60E3 Q37821897-1269F5FD-C4CF-47AD-8426-C421EC55F703 Q37827340-15EFF2BA-FAF0-4063-8AC0-4992D2528BA6 Q37854068-085C55CB-8F47-46F8-A413-D605D857B007 Q37996079-05037010-2127-4A48-9375-6BDC8C6D2959 Q38021684-44B73545-50B2-44B7-9768-2522BB3466EA Q38061964-323BBB82-AC8A-4A9B-A759-D116C920CD64 Q38261469-CB6E53D0-7707-4A26-86B0-0E896815CDC2 Q38393154-E23F26AF-8A9D-49F7-8114-C19F0AF5EB95 Q38995713-10363275-76CE-4347-B641-BE7EF6DAAAA8 Q39257360-4F2C2C3E-05A0-435D-B5B1-535A3BE90195 Q39454208-A90495EE-592B-4831-B887-260AB7066929 Q39689222-80B6BB63-04C1-4339-90F4-786C5FE7D2A3 Q42647696-742D18CA-E1AA-4694-8650-0A975DBA80C7 Q49993915-7238584E-06C7-439F-97FF-181F030B9B65 Q52297317-7164D3C6-CC58-4742-92FE-5C36A29EDD35

P2860

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

http://www.wikidata.org/entity/Q36510153

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@ast

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@en

type

label

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@ast

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@en

prefLabel

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@ast

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@en

P1433

Q36510153-EE4D88CE-FA95-4890-95DF-BD57AF64A1FE

P1476

Q36510153-DFA26AC9-67A9-450D-8E41-06B35A670723

P2093

Q36510153-0A1B65A3-9F61-451C-A9F8-8B268A5A0D14

Q36510153-2013A1A6-A881-4E59-9C5F-A6E01D6A0842

Q36510153-49AE6300-551C-4636-B753-FA8672EA303E

Q36510153-56D6EFDE-3CF2-45F3-962B-C53A6F91C639

Q36510153-5CB9C2F4-1CB7-46D7-9936-5C21AE786C99

Q36510153-77190293-9D77-4BC9-BC31-A55F9E29984D

Q36510153-98380488-BC0B-4C8F-BB48-BD3BD0D7C3C7

Q36510153-9930E076-7FB4-4EAB-B513-98D36B0783BC

Q36510153-A9987B1F-0891-4CEC-8AC5-2392EC2D7F55

Q36510153-AE38E191-5EFD-45C3-9C0C-069233F2D3D7

P2860

Q36510153-05EDF5B3-C722-4032-A108-8DBAD853C2EB

Q36510153-14014623-6DDB-46EE-AB15-7671858C1FFD

Q36510153-1AEEA33E-5FE0-4357-81A5-86D630D4E98B

Q36510153-1E943231-7981-499A-8D94-4B089FD7C07A

Q36510153-1F90612A-0FD0-47C3-822B-54D3E0AE23B8

Q36510153-3C9DCD40-4F29-4C79-9F52-B9C99F1E22BB

Q36510153-448F0984-F352-4CC9-B634-2B22B41469D5

Q36510153-58A908C3-F387-40F6-8E80-BD433F7B2A8C

Q36510153-60371A97-9C14-49D4-8A3F-ECBA6717ABFE

Q36510153-63BC3FCB-BBBC-4236-A05D-F87D71B82C00

P2888

Q36510153-A966B980-F355-4DBE-B2EE-72447099D370

P304

Q36510153-086A3DAA-A8CA-4530-B120-2997DC91C4C3

P31

Q36510153-C1179C45-11F3-450E-8350-F0E9CCBA9436

P356

Q36510153-2C456E93-2493-4FC2-9A6B-FACFC4D4118F

P407

Q36510153-F9C31E3B-8101-4D09-9364-95CE83F8BB52

P433

Q36510153-DAEDA86E-D841-4B7D-A443-59CE2D80CE94

P478

Q36510153-144577C1-0EDD-4721-BBF5-FBEBCD5D4AA4

P577

Q36510153-772B9F54-5FD6-4801-8ACA-319816D1C77E

P5875

Q36510153-13FD6B7E-CA27-4FC6-A6ED-6492960EA0F6

P698

Q36510153-61CBCC6F-B3C2-4774-8DA9-0B1888607D40

P932

Q36510153-8EC1BF83-9B00-4BBF-9DAC-0D1A9A5C361B

P356

P1433

British Journal of Cancer

P1476

Activity of lapatinib a novel ...... uman endometrial cancer cells.

@en

P2093

C Ginther

http://www.w3.org/2001/XMLSchema#string

D J Slamon

http://www.w3.org/2001/XMLSchema#string

D Toft

http://www.w3.org/2001/XMLSchema#string

G E Konecny

http://www.w3.org/2001/XMLSchema#string

G Yang

http://www.w3.org/2001/XMLSchema#string

J Dering

http://www.w3.org/2001/XMLSchema#string

K C Podratz

http://www.w3.org/2001/XMLSchema#string

M Rahmeh

http://www.w3.org/2001/XMLSchema#string

M Schoenberg Fejzo

http://www.w3.org/2001/XMLSchema#string

N Venkatesan

http://www.w3.org/2001/XMLSchema#string

P2860

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

Complex networks orchestrate epithelial-mesenchymal transitions

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Rare uterine cancers.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature.

Cadherins and catenins in breast cancer.

P2888

P304

1076-1084

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604278

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5517282

http://www.w3.org/2001/XMLSchema#string

P698

18334972

http://www.w3.org/2001/XMLSchema#string

P932

2275492

http://www.w3.org/2001/XMLSchema#string